Clinical trials: Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver
Feasibility of VIIT in Adults With NASH
The purpose of this study is to determine whether patients with stage 1-3 NASH-related fibrosis are able to complete a single vigorous-intensity interval training (VIIT) session on an indoor rowing machine and provide blood…
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Diseases
- Trial name
- NCT03861819
- Testing
- Vigorous-intensity interval training (VIIT)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Liver Neoplasm, HBV Infection
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma…
- Conditions
- Liver Neoplasm, HBV Infection, Non-alcoholic Fatty Liver Disease NAFLD, Liver Fibrosis
- Trial name
- NCT07265544
- Testing
- Collection of Preoperative Peripheral Blood, Collection of Discarded Liver Tissue During Surgery
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Post-cholecystectomy Metabolic Changes -Hepatic Steatosis
Fatty Liver in Long Standing Cholecystectomy
This observational study aims to evaluate the association between long-term cholecystectomy and the development of metabolic dysfunction-associated fatty liver disease (MAFLD) in adult patients.
- Trial name
- MAFLD-Chole St (NCT07284004)
- Volunteers
- 100 people
- Sponsor
- Yasmeen Ahmed Farrag Ahmed
Obesity, Childhood, NAFLD
Can Fecal Calprotectin Be Used as a Biomarker of Non-alcoholic Fatty Liver Disease In Obese Adolescents?
The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that ongoing inflammation in obesity and alterations in the enterohepatic axis contribute to this process.
- Trial name
- NCT06229184
- Testing
- Fecal Calprotectin Test
- Where
- Turkey (Türkiye)
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
the Effect of NAFLD on CHB
A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease.
This is a prospective/retrospective, observational follow-up study of effects of fatty liver on chronic hepatitis B. Patients will join this study who undergo transient elastography with liver stiffness (LS) and CAP measurements…
- Trial name
- NCT05255978
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Qin Ning
Non Alcoholic Steatohepatitis (NASH)
A Phase 2b Study of Icosabutate in Fatty Liver Disease
A Phase 2b study to evaluate the efficacy of different doses of NST-4016 on the resolution of NASH without worsening of fibrosis
- Trial name
- ICONA (NCT04052516)
- Testing
- Icosabutate
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 280 people
- Sponsor
- NorthSea Therapeutics B.V.
Chronic Hepatitis B, Nonalcoholic Fatty Liver Disease
Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD
The changes in liver function, body mass index, controlled attenuation parameters, liver stiffness and HBV-DNA at different time points in each group before and after treatment were counted to explore the clinical efficacy of…
- Trial name
- NCT05523648
- Testing
- Chronic Hepatitis B
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sichuan Leshan Traditional Chinese Medicine Hospital
Overweight, Obese
The Effect of Protein-enriched Diet on Body Composition and Appetite
Obesity is a major problem worldwide and current dietary interventions are not proving to be enough to cease the increase in levels of obesity and its detrimental side effects, such as nonalcoholic fatty liver disease (NAFLD).
- Conditions
- Overweight, Obese, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease
- Trial name
- ProteinRich (NCT01634048)
- Testing
- High Protein, low calorie meal replacement
- Where
- United Kingdom
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Imperial College London
NAFLD
Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a spectrum of hepatic disease ranging from fat accumulation in liver to fibrosis and cirrhosis. It affects 25% of the world population on average.
- Trial name
- NCT05521633
- Testing
- Metformin and Pioglitazone
- Where
- Pakistan
- Volunteers
- 96 people
- Sponsor
- King Edward Medical University
Nonalcoholic Fatty Liver Disease
Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in affluent countries. It may progress to cirrhosis and liver cancer. At present, there is no approved drug for NAFLD.
- Trial name
- NCT00868933
- Testing
- Low glycemic index dietary intervention program, simple lifestyle advice
- Where
- China
- Volunteers
- 159 people
- Sponsor
- Chinese University of Hong Kong
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults
The goal of this randomized control trial study is to compare an acceptance-based weight loss program with an occupational therapy behavioral lifestyle modification intervention in adults with metabolic associated-dysfunction…
- Trial name
- NCT06121999
- Testing
- Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Grand Valley State University
Non-Alcoholic Fatty Liver Disease
Ambulatory Liver Fat Monitoring in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population and causes serious complications, including cirrhosis, hepatocellular carcinoma or mortality.
- Trial name
- NCT05754385
- Testing
- Ambulatory monitoring of liver fat, Standard of care
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The University of Hong Kong
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal
This research is being done to find out if aerobic exercise is beneficial in reversing scarring. Physical activity has been shown to increase fitness in healthy individuals as well as in those with NASH.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NASH-FITTER (NCT03864835)
- Testing
- Moderate intensity aerobic exercise
- Sponsor
- Milton S. Hershey Medical Center
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects
This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing single doses
- Trial name
- NCT02612662
- Testing
- AZD4076
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity, Fatty Liver
Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
To evaluate the impact of a Low Carbohydrate Ketogenic Diet (LCKD) weight loss program and compare to the standard of care program established for patients with Non-Alcoholic Fatty Liver Disease (NAFLD) on: (1) Liver fat and…
- Conditions
- Obesity, Fatty Liver, Ketogenic Dieting
- Trial name
- NCT03141008
- Testing
- Fibroscan changes with different diets
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Non-Alcoholic Fatty Liver Disease, NAFLD
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
- Trial name
- SLIDE (NCT03867487)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
Non-Alcoholic Fatty Liver Disease
FCI Effectiveness in NAFLD Stratification
The goal of this pilot study is exploring whether field-cycling imaging may be able to detect characteristics of liver disease in patients with different degree of non-alcoholic fatty liver disease (NAFLD) that could be important…
- Trial name
- FIELDS (NCT05827432)
- Testing
- Field-cycling imaging (FCI)
- Where
- United Kingdom
- Sponsor
- NHS Grampian
NAFLD (Nonalcoholic Fatty Liver Disease)
Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries.
- Trial name
- NCT07900087
- Testing
- Roflumilast
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease
A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.
- Trial name
- NCT03350165
- Testing
- K-877
- Where
- 16 sites in Japan
- Volunteers
- 118 people
- Sponsor
- Kowa Company, Ltd.
Nonalcoholic Fatty Liver Disease
Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores
Patients will be randomized to lifestyle changes alone or lifestyle changes associated with iron depletion. Iron depletion will be achieved by removing 350 cc of blood every 10-15 days according to baseline hemoglobin values and…
- Trial name
- NCT00658164
- Testing
- Iron depletion treatment
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.